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A B S T R A C T
The present study examined the factor structure of the Hungarian version of the Medication Adherence Rating
Scale (MARS) and analyzed its association with socio-demographics, insight, internalized stigma, and the ex-
perience of loss and grief as a result of the mental illness diagnosis, using confirmatory factor analysis (CFA) with
a series of one covariates at a time. Mentally ill patients (N=200) completed self-report questionnaires. CFA
supported the original three-factor structure although one item was moved from its original factor to another.
Lower insight, higher internalized stigma, loss, and grief were significant predictors of lower treatment ad-
herence. Lower adherence was found to be significantly associated with lower quality of life. No difference in
adherence was found between different diagnostic groups, which stresses the need to examine non-adherence in
the wider spectrum of mental diagnosis. The study also stresses the importance of patients’ subjective experience
in promoting better adherence, and raises the need to address the experience of stigma but also of less studied
experiences, such as patients‘ feelings of loss and grief. Integrating these experiences in intervention programs
might have meaningful implications for the improvement of treatment adherence and patients’ quality of life.
1. Introduction
Psychiatric medications are often the first line of treatment offered
to mentally ill patients (Gilbert et al., 1995) due to their fundamental
contribution to symptom relief and to patients’ rehabilitation
(Corrigan, 2004; Tsang et al., 2006). However, despite its advantages,
non-adherence is highly prevalent among mentally ill patients. In fact,
compared to patients who are receiving treatment for physical condi-
tions, mental patients are the least likely to adhere their medication
regimen (Fenton et al., 1997; Keck et al., 1996; McDonald et al., 2002;
Scott and Pope, 2002).
Adherence is “the extent to which a person‘s behavior-taking med-
ication, following a diet, and/or executing lifestyle changes, corre-
sponds with agreed recommendations from a health care professional”
(p.3, World Health Organization, 2003). Additionally, adherence
should be regarded as a range of behaviors from complete adherence to
medication, through partial adherence, to complete non-adherence
(Fialko et al., 2008). Non-adherence to psychiatric medications is
known to have detrimental consequences for both patients and society,
including increased symptom severity, relapses, re-hospitalizations,
suicides, and reduced quality of life (Ernst and Goldberg, 2004;
Perkins, 2002; Puschner et al., 2009; Sajatovic et al., 2004;
Svarstad et al., 2001; Weiden and Olfson, 1995). Its consequences for
society is mainly through the loss of income of patients and the high
costs of healthcare (Weiden and Olfson, 1995).
In order to assess medication non-adherence, a variety of methods
have been utilized. Among them are “subjective methods” such as pa-
tient and clinician reports, and “objective methods” such as pill counts,
electronic monitoring, and serum level measures (Velligan et al., 2006).
However, it appears that there is no clear consensus regarding which
method is preferable because each of them has its’ particular short-
comings (Velligan et al., 2006). Patients’ self-reports have been criti-
cized for being influenced by memory deficits and social desirability
bias (Sajatovic et al., 2010; Yang et al., 2012). However, patient self-
reports are considered to be the most efficient due to (i) their non-
intrusive and easy to administer nature, (ii) the low investment in terms
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of cost which is required to use them, and (iii) them being considered
highly informative regarding individual adherence problems
(Fialko et al., 2008).
The Medication Adherence Rating Scale (MARS) (Thompson et al.,
2000) is a useful self-report scale that was developed to assess ad-
herence among psychiatric populations. With the goal of developing
more reliable, valid, and comprehensive tool for assessing adherence,
including behavior and attitudes, Thompson et al. (2000) used two
well-established self-report scales, the 30-item Drug Attitudes Inventory
(DAI) (Hogan et al., 1983) and the four-item Medication Adherence
Questionnaire (MAQ) (Morisky et al., 1986), to construct the MARS.
The scale score ranges from 0 (low likelihood of medication adherence) to
10 (high likelihood of medication adherence) reflecting the continuous
nature of adherence (Fialko et al., 2008). Previous exploratory factor
analysis suggested a three-factor structure: (i) medication adherence in
terms of behavior, (ii) medication adherence as reflected from ones
attitudes, and (iii) individuals’ attitudes towards psychiatric medica-
tions and their negative side-effects (Thompson et al., 2000). This
structure was also supported by an additional validation study
(Fialko et al., 2008).
When examining non-adherence, understanding its underlying fac-
tors is vital in order to properly address it. Among the leading factors
concerning non-adherence are poor insight, shorter illness duration,
negative attitudes toward medication, lack of social support, and
medication side-effects (Diaz et al., 2004; El-Mallakh, 2007; Lacro et al.,
2002; Olfson et al., 2006). Internalized stigma – the adoption of ste-
reotypes by mental patients themselves (Corrigan et al., 2009) – is
another well-studied factor compromising adherence (Hajda et al.,
2016; Livingston and Boyd, 2010; Yılmaz and Okanlı, 2015) because it
makes patients ashamed and individuals would rather not take their
medication than being labeled as “mentally ill” (Corrigan, 2004).
Grief (which although being commonplace among patients) and its
impact on adherence, has never been previously examined. Grief can be
experienced as a result of the mental illness due to many different types
of loss (e.g., loss of functioning, relationships, sense of self, and dreams
for the future) (Appelo et al., 1993; Lewis, 2004; Mauritz and van
Meijel, 2009; Stein, 2005; Stein et al., 2005; Wittmann and
Keshavan, 2007). Examining grief as a consequence of mental illness is
meaningful especially as grief is known to be related to reduced psy-
chological wellbeing, physical health, and suicidality (Miles, 1985;
Moore et al., 1988; Porritt and Bartrop, 1985; Szanto et al., 2006) and
was recently found to be associated with loneliness and lower quality of
life, specifically among mentally ill patients (Buchman-Wildbaum et al.,
2020). Most importantly, grief which is known to include behavioral
avoidance, negative cognitions, and emotional reactions to loss
(Horowitz et al., 1981), is thought to negatively affect adherence. For
example, previous research involving individuals with schizophrenia
reported difficulties in accepting the diagnosis and the need for treat-
ment, avoidant behaviors, and distress (Mauritz and van Meijel, 2009).
Therefore, the possibility that it impacts and hinders patients’ medi-
cation-taking, requires further research.
The first main goal of the present study was to further examine the
factor structure of the MARS among a non-English speaking psychiatric
population. Although non-adherence is prevalent in the wider spectrum
of mental diagnosis (Colom et al., 2005; Gilmer et al., 2004; Lingam and
Scott, 2002; Melfi et al., 1998), previous studies using the MARS have
mostly been conducted among schizophrenia patients (Fialko et al.,
2008; Jaeger et al., 2012; Thompson et al., 2000). Therefore, examining
its measurement model among patients with other psychiatric diag-
noses is needed.
The second main goal was to examine the possible predictors of non-
adherence in order to gain a better insight regarding the different ways
by which it can be reduced or avoided. More specifically, the present
study focused mainly on insight, internalized stigma, loss, and grief. It
was expected that lower insight, increased internalized stigma, loss, and
grief would all be significant predictors of non-adherence. The impact
of non-adherence on patients’ lives was also examined, and it was ex-




The present study's sample comprised 200 individuals with a diag-
nosis of psychiatric disorder who were receiving routine mental care in
an outpatient division of a mental health center in Budapest, Hungary.
The inclusion criteria were: (i) having a mental health diagnosis ac-
cording to the ICD-10 (World Health Organization, 1992), (ii) being
consumers of psychiatric medications, (iii) being inpatients or out-
patients in any form of psychiatric care, (iv) being patients who had not
been abusing illicit substances and alcohol for a period of at least two
weeks at the time of evaluation, (v) being in the age range 18 to 65
years, and (vi) having (based on their psychiatrist's view) the capability
to answer the questionnaire. The exclusion criteria were (i) being at a
severe (i.e., acute) phase of the illness, (ii) being diagnosed with an
organic brain disorder, dementia, and/or mental retardation, and (iii)
not having the mental capability and/or capacity to answer the self-
report questionnaire or provide informed consent.
2.2. Procedure
The psychiatrists at the mental health center contacted and invited
eligible patients to participate in the study. They supplied important
information about the study, including the study's goals which were
communicated both verbally and in writing. Patients who agreed to
participate in the study were asked to sign an informed consent sheet
and then to complete a self-report questionnaire. The study ques-
tionnaires were all translated from English to Hungarian and back
translated from Hungarian to English. Any possible inconsistencies
between the original and back-translated version were addressed and
solved. The present study was given ethical approval by the ethical
board of the regional hospital accountable for the patients’ welfare.
2.3. Measures
2.3.1. Socio-demographic questions
In the present study, different factors were evaluated such as the
participant's gender, age, education (finished/did not finish high
school), employment status (employed/unemployed), psychiatric di-
agnosis, marital status (married/divorced/widowed/single) and history
of former hospitalizations (yes/no). Patients were allocated into six
diagnostic groups based on their diagnosis and following the ICD-10
codes classification (World Health Organization, 1992): (i) schizo-
phrenia spectrum disorders (e.g., schizophrenia, schizotypal and delu-
sional disorder), (ii) mood disorders (e.g., major depressive disorder,
bipolar and manic disorder), (iii) stress-related disorders (e.g., phobic
anxiety disorders, obsessive- compulsive disorders, somatoform dis-
orders), (iv) behavioral syndromes associated with physiological dis-
turbances (e.g., eating disorders), (v) personality disorders (e.g., bor-
derline personality disorder, avoidant personality disorder), and (vi)
disorders due to psychoactive substance use.
2.3.2. Adherence
The Medication Adherence Rating Scale (MARS) (Thompson et al.,
2000) is a 10-item scale that encompasses three adherence elements; (i)
adherence in terms of behavior (Items 1-4), (ii) adherence in terms of
attitudes (Items 5-8), and (iii) attitudes towards psychiatric medications
and their negative side-effects (Items 9 and 10). The scale includes ten
yes/no items, and the scoring depends on whether the individual in-
dicates adherence or non-adherence; those responses implying ad-
herence are coded as 1, while those responses implying non-adherence
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are coded as 0. The scores of the ten items are summed up to produce
total score which ranges from 0 (low likelihood of medication ad-
herence) to 10 (high likelihood of medication adherence) (Fialko et al.,
2008). In the present study the scale found to have adequate internal
consistency (Cronbach α=0.61).
2.3.3. Insight
The Birchwood Insight Scale (BIS) (Birchwood et al., 1994) is a brief
eight-item self-report measure which assesses three dimensions of in-
sight into mental illness: illness awareness (Items 2 and 7), need for
treatment (Items 3,4,5 and 6), and re-labelling of symptoms (Items 1
and 8). Each item contains a statement with three response options (i.e.,
agree, unsure or disagree). Participants’ responses on each item is
scored depending on the insight level it indicates, where responses in-
dicating good insight (agree/disagree) are scored as 2, unsure responses
are scored 1, and responses which indicate poor insight are scored as 0.
In the present study two changes were made. First, because the study
participants were not hospitalized, a minor modification was made in
the item presuming hospitalization (Item 4) (“My stay in the hospital is
necessary” was amended to “The treatment in the institution is neces-
sary”). Second, in light of findings in a previous validation study from
Hungary reporting on two-factor structure (‘illness awareness’ and
‘need for treatment’) (reference blinded for peer review purposes) the
present study only examined these factors. The BIS in the current
sample found to have moderate internal consistency (Cronbach
α=0.69; illness awareness: Cronbach α=0.54; need for treatment:
Cronbach α=0.64).
2.3.4. Internalized stigma
The Self Stigma of Mental Illness Scale (SSMIS) (Corrigan et al.,
2006), assesses the four stages process of stigma internalization sug-
gested by Corrigan et al. (2006), and included them as subscales: (i)
individual's awareness of stigma concerning mental illness held by the
society, (ii) individual's agreement with these stigmatic beliefs, (iii)
individual's adoption of these beliefs into their own personal identity,
and (iv) resultant decrease in an individual's self-esteem. Participants
rate their agreement with 10 statements included in each one of the
four subscales on a nine-point Likert scale ranging from 1 (strongly
disagree) to 9 (strongly agree). Each subscale includes a total score ran-
ging between 10-90, and higher scores indicates greater acceptance of
stigma as indicated by the specific subscale. The scale was found to
have good internal consistency in the present study (stigma awareness:
Cronbach α=0.92; stigma agreement: Cronbach α=0.90; stigma in-
ternalization: Cronbach α=0.83; self-esteem reduction: Cronbach
α=0.84)
2.3.5. Grief
Grief was assessed using the Mental Illness Version of the Texas
Inventory of Grief (MIV-TIG) (Miller et al., 1990). The MIV-TIG is an
adapted version of Texas Revised Inventory of Grief (TRIG)
(Faschingbauer et al., 1977) which is used to assess grief reaction to the
death of a loved one. The MIV-TIG was modified to assess grief as a
result of a relative's mental illness and the loss of that individual as s/he
was before the development of mental illness (Miller et al., 1990). The
scale includes the different known expressions of grief such as persistent
emotional distress, being constantly occupied with the lost person, and
difficulties and unwillingness to acknowledge and accept the reality of
the loss. The MIV-TIG comprises eight items evaluating initial grief and
16 items evaluating current grief (i.e., 24 items in total). The present
study only utilized the 16 items focusing on current grief. Furthermore,
as the present study assessed grief of mental patients themselves and
not of their relatives, a minor adjustment of the items was made,
manifested in first account statements (e.g., “I am preoccupied with the
thoughts of how I could have been if not for the illness”) similar to previous
modifications (Patterson et al., 2005). Participants were asked to re-
spond to the items based on a five-point Likert scale ranging from
‘completely true’ to ‘completely false’. Item scores are summed up into a
total score, where higher scores reflect higher grieving (Miller et al.,
1990). Excellent internal consistency was found in the present study
(Cronbach α=0.95).
2.3.6. Perceived loss as a result of mental illness
The Personal Loss from Mental Illness (PLMI) Scale was developed
to assess individuals’ perception of loss resulting from their mental
illness (Stein et al., 2005). Four factors in the scale structure have been
identified: ‘loss of roles and routines’, ‘loss of former relationships’, ‘loss
of former self’ and ‘loss of future’ (Stein et al., 2005). The scale com-
prises 20 items asking about respondents’ agreement with statements
regarding the losses experienced by individuals with mental illness.
Participants agreement levels can range from 1 (strongly disagree) to 5
(strongly agree). Item scores are summed up to generate subscale and
total scores, where higher scores indicate higher perception of loss.
Excellent internal consistency of the scale was found in the present
study (Cronbach α=0.90).
2.3.7. Quality of life
The Manchester Short Assessment of Quality of Life (MANSA)
(Priebe et al., 1999) is shortened version of the Lancashire Quality of
Life Profile (LQLP) (Oliver et al., 1997). The MANSA comprises 16
questions, with four categorized as “objective” (asking about facts such
as being accused for a crime) answered dichotomously (yes/no), and 12
categorized as “subjective” (asking about life satisfaction in general and
specific different aspects of life) answered on a seven-point rating scale
of satisfaction, ranging from 1 (couldn't be worse) to 7 (couldn't be better).
Total scale score is the mean average of the 12 question scores, where
higher scores indicate a better quality of life. The scale had very good
internal consistency in the present study (Cronbach α=0.87).
2.4. Statistical analyses
In order to assess the factor structure and item performance of the
Hungarian version of the MARS in the current sample, a series of
confirmatory factor analyses (CFAs) were conducted. MARS items were
regarded as categorical and used the mean-adjusted and variance-ad-
justed weighted least squares (WLSMV) estimator. In CFA, an appro-
priate degree of fit means that the comparative fit index (CFI) and the
Tucker-Lewis Index (TLI) should be close to 0.95, whereas model in-
dices of <0.90 means that the model should be declined
(Brown, 2006). The next fit index used was root mean squared error of
approximation (RMSEA). RMSEA lower than 0.05 implies excellent fit,
a value around 0.08 implies adequate fit, and a value above 0.10 im-
plies poor fit (Browne & Cudek, 1993). After calculating the factor
scores, a comparison for statistical difference in factor scores between
groups with different diagnosis were conducted. Next, a series of CFAs
with single covariate models were performed to examine the associa-
tions between adherence, sociodemographic factors, insight, inter-
nalized stigma, grief, and loss. This approach was chosen due to its
ability to prevent the problem of multicollinearity. Finally, the asso-
ciation between the adherence factors and quality of life was in-




Table 1 presents the percentages, means, and standard deviations
(SDs) of the different variables used in the present study. The current
sample was dominated by women and high school graduates. The
predominant mental illness diagnosis was stress-related disorders, and
almost half of the participants had previous hospitalizations in their
history. The sample was diverse in terms of age (ranges from 32 to 56
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years), with a mean of 44.2 years (SD=11.8).
3.2. Confirmatory factor analysis of the Medication Adherence Rating Scale
(MARS)
A series of confirmatory factor analysis with items as categorical
indicators and WLSMV estimator were performed. The first model in-
cluding only one factor yielded unacceptable degree of fit. The second
model was the original three-factor model which had close to accep-
table degree of fit (see Table 2 note). Inspecting the factor structure,
modification indices and the content of the items, Item 5 was removed
(“I take my medication only when I am sick”) from the adherence attitude
factor to the adherence behavior factor. The error covariance between
Item 1 (“Do you ever forget to take medication?”) and Item 2 (“Are you
careless at times about taking your medication?”) was allowed. The size of
the correlations between the uniqueness of these two factors was large
(r=0.76). These modifications yielded excellent degree of fit in all fit
indices. The factor loadings of the original (Model 2) and modified
(Model 3) measurement models are presented in Table 2. The means of
factor loadings of each factor in the modified model were 0.63, 0.62,
and 0.87 respectively. Internal consistencies of the factors were: be-
havior: Cronbach α=0.64, attitude: Cronbach α=0.44, side-effects:
Cronbach α=0.61.
3.3. Medication adherence in different diagnostic groups
After calculation of factor scores, adherence dimensions were
compared across three diagnostic groups, and no significant main effect
was found (see Table 3). However, comparison between the schizo-
phrenia spectrum disorders group and the other two groups together,
showed that schizophrenia patients reported higher score of adherence
behavior than the other groups together (see Table 3 note). The same
analyses with the attitude and side-effects resulted in much smaller
difference.
3.4. Covariates of medication adherence: Single covariate models
The predictors of the dimensions of adherence were tested in a
series of CFAs with single covariate models. In these models, only one
predictor was entered in each model. The standardized regression
coefficients are presented in Table 4. Covariates were gender, age, in-
sight, internalized stigma, loss, and grief. Higher insight (“need for
treatment factor”) predicted significantly higher adherence (adherence
behavior and attitude). Higher stigma predicted significantly lower
adherence. Especially adopting stigmatic views into self-identity and
self-esteem reduction were associated with lower adherence behavior,
attitude, and lower tolerance of side-effect. Furthermore, awareness of
(and agreement with) stigmatic views were associated with lower tol-
erance of side-effects of the treatment. Similarly, higher loss and higher
Table 1
Descriptive statistics of the sample
Gender (female) N (%) 133 (66.5)
Age – mean (SD) 44.2 (11.8)
Education, graduated high school – N (%) 157 (78.5)
Previous hospitalizations – N (%) 89 (44.5)
Diagnosis
Schizophrenia spectrum disorders – N (%) 53 (26.5)
Mood disorders – N (%) 58 (29.0)
Stress-related disorders – N (%) 89 (44.5)
Personality disorders – N (%) 10 (5.0)
Disorders due to psychoactive substance use – N (%) 2 (1.0)
Behavioral syndrome associated with physiological disturbances – N
(%)
2 (1.0)
Only one diagnosis- N (%) 188 (94.0)
Two diagnoses- N (%) 10 (5.0)
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grief were associated with lower adherence in terms of lower tolerance
of side-effects.
3.5. Correlations between adherence and quality of life
Adherence was expected to be associated with quality of life. Due to
the medium-sized correlations among adherence factor and possible
multicollinearity, instead of the traditional regression analysis to pre-
dict quality of life, the focus was only on the correlations of the con-
struct. Increased behavior and tolerance of side-effect aspects of ad-
herence correlated significantly with increased quality of life (r=0.24
p<.01 and r=0.25 p<.01, respectively). When the correlations be-
tween behavior and side-effect aspects of adherence (r=0.535) were
controlled for, the remaining partial correlations were still significant
(r=0.13, p<.05 and r= 0.15, p<.05, respectively).
4. Discussion
The present study confirmed the three-factor structure of the
Medication Adherence Rating Scale (MARS) (Fialko et al., 2008;
Thompson et al., 2000) among non-English speaking patients with
different diagnoses. However, a minor modification was required,
namely Item 5 (“I take my medication only when I am sick”) should be
removed from the ‘attitude’ factor and added to the ‘behavior’ factor. In
addition to the psychometric considerations, the content of this item
also warranted this change. Similar change was proposed in a valida-
tion study of the Taiwanese version of the MARS (Kao and Liu, 2010).
However, in the Taiwanese study, the MARS was found to have two
factors (adherence behavior and subjective response to medications),
which reinforce the need for further examination of the scale among
different populations from different cultural backgrounds.
The present study also examined possible differences in adherence
among different diagnoses. Participants from the three major diagnostic
categories did not differ in the three adherence scores. However, based
on the results, it is possible that the sample size was not large enough to
allow the detection of small differences among diagnostic groups. This
finding conflicts with the literature claiming that the problem of non-
adherence is especially higher among those with schizophrenia
(Cramer and Rosenheck, 1998; Sajatovic et al., 2010; Taj et al., 2008;
Tesfay et al., 2013). However, this finding might be also the result of
the inclusion of participants who were not hospitalized and in a stable
state, and therefore cannot be generalized to the wider schizophrenia
patient population.
The findings of the present study also provide important new
knowledge about the less frequently studied predictors of adherence.
The present study is the first to find that patients’ experience of loss and
grief significantly (negatively) influenced their adherence to treatment.
Although loss and grief were reported as the main experiences of pa-
tients by mental health professionals over the years (Appelo et al.,
1993; Lewis, 2004; Wittmann and Keshavan, 2007; Young et al., 2004),
this body of research was neglected and instead research interest was
devoted mainly to the loss and grief experienced by family members of
individuals with mental disorders (e.g., Davis and Schultz, 1998;
Miller et al., 1990; Ozgul, 2004). Only recently was this important topic
revived with the development of the Personal Loss from Mental Illness
Scale (PLMIS) (Stein et al., 2005) and novel findings associating the
experience of loss with higher loneliness, lower recovery rates, and
lower quality of life (Buchman-Wildbaum et al., 2020; Potokar, 2008;
Stein et al., 2005).
A recent study also confirmed the association between loss and
higher grief among patients with mental disorders (Buchman-
Wildbaum et al., 2020). That study was also the first to examine grief
among patients themselves, and the first to report that it is associated
with higher loneliness and lower quality of life. Grief might interfere
with medication-taking due to its nature, including emotional distress
regarding the loss, behavioral avoidance, and denial of the new reality
and the adjustments that need to be taken (Horowitz et al., 1981).
Furthermore, a previous study reported that among schizophrenia pa-
tients, grief manifested in difficulties in accepting the existence of the
diagnosis and need for treatment and in withdrawal and avoidance
(Mauritz and van Meijel, 2009). The taking of medication might be a
painful and troublesome daily reminder of their status of “mentally ill”,
the losses they experienced, who they used to be before the illness, and
all their previous dreams for the future. Under the influence of grief and
the strong difficulty to accept the fact that they have an illness, ac-
ceptance of the need to take medications might be comprised. It is in-
teresting to note that in the present study, both loss and grief were
specifically related to the adherence aspect affected by negative
Table 3
Comparison of adherence dimensions across diagnostic groups.
Dimensions of adherence* Schizophrenia spectrum disorders N=51 Mean
(SD)
Mood disorders N=56 Mean
(SD)
Stress-related disorders N=84 Mean
(SD)
F p Effect size f
Behavior 0.03 (0.31) -0.07 (0.34) -0.08 (0.37) 1.77 0.1737 0.08
Attitude 0.01 (0.31) -0.03 (0.33) -0.04 (0.34) 0.38 0.6843 0.04
Side effects -0.06 (0.57) -0.12 (0.54) -0.12 (0.59) 0.21 08134 0.04
Note: *Factor scores were used in the calculation. f: effect size index, An f = 0.10 is a small effect and an f = 0.25 is a medium effect (Cohen, 1988). f values for group
comparisons: Behavior: Schizophrenia versus Mood disorder: f=0.06; Schizophrenia versus stress-related disorder: f=0.08; mood disorder versus stress-related
disorder f=0.01. Attitude: Schizophrenia versus Mood disorder: f=0.03; Schizophrenia versus stress-related disorder: f=0.04; mood disorder versus stress-related
disorder f=0.01. Side effects: Schizophrenia versus Mood disorder: f=0.03; Schizophrenia versus stress-related disorder: f=0.03; mood disorder versus stress-related
disorder f=0.00. Comparison between the schizophrenia spectrum disorders group and the mood and stress-related disorders together, showed that schizophrenia
patients reported higher score of adherence behavior than the other groups together (t[186]=1.93, p=0.055, Cohen's d=0.33). The same analyses with the attitude
and side-effects resulted in much smaller effect size estimates (Cohen's d=0.16 and 0.11 respectively).
Table 4
Covariates of medication adherence: Single covariate models#
Dimensions of medication adherence
Covariates Behavior Attitude Side effect
Age 0.15 0.10 0.08
Gender 0.04 -0.05 -0.21
Grief (MIV-TIG) -0.10 -0.01 -0.45***
Internalized stigma
Awareness of the stigmatic views -0.14 0.10 -0.22*
Agreement with the stigmatic views -0.09 -0.04 -0.23*
Adopting stigmatic views into self-
identity
-0.35*** -0.19* -0.24*
Self-esteem reduction -0.30** -0.27* -0.21*
Personal loss (PLMI) -0.16 -0.02 -0.29**
Insight
Illness awareness -0.10 0.08 -0.12
Need for treatment 0.30** 0.49*** 0.09
Note: #: CFA with single covariate models include only one covariate, therefore
each line of the table represents one model. Standardized regression coeffi-
cients. Medication adherence dimensions are used as latent variables and
covariates are used as observed variables. *p<.05; **p<0.01; ***p<.001.
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attitudes regarding the side-effects of medications. While it is possible
that more significant results regarding adherence aspects might be
more likely to have found among a larger sample, this finding is highly
informative. Out of the adherence aspects, this aspect of the influence of
medications might be the most concrete and vivid reminder for their
illness and therefore it is specifically and strongly associated with grief.
Previous studies have already reported that side-effects of medications
negatively influencing individuals’ adherence behavior (Perkins, 2002;
Perlick, 2004; Robinson et al., 2002; Sajatovic et al., 2011). Further-
more, Mauritz and van Meijel (2009) found that the negative influence
of medications was related to feelings of loss and grief in schizophrenia.
The findings of the present study may contribute to the extant lit-
erature by implying that it is not necessarily the actual side-effects of
medications but the grief and the difficulty to accept their illness and
the need in medications, which is associated with higher tendency to
perceive medications as having negative influence, irrespective of
medications having more or less side-effects. This in turn might reduce
their probability of adherence. However, due to the preliminary nature
of the present study, more research is needed on the topic of loss and
grief in mental health and its influence.
The present study also found that insight into mental illness is a
significant predictor of better adherence, in line with previous literature
(e.g., Beck et al., 2011; David et al., 1992; Kao and Liu, 2010) and with
the proposition that better insight leads to better understanding of the
need for treatment and to better adherence (Beck et al., 2011;
Droulout et al., 2003; Kozuki and Froelicher, 2003; Lysaker et al., 2018;
Misdrahi et al., 2012; Mohamed et al., 2009; Yen et al., 2005). The
present study found that only the insight aspect of ‘awareness of the
need for treatment’ was significantly associated with adherence (as
manifested in patients' behavior and their attitudes) while ‘awareness of
the illness’ aspect did not predict any dimensions of adherence. This is
in line with studies reporting that awareness of the need for medication
leads to better adherence (Kao and Liu, 2010; Misdrahi et al., 2012;
Mutsatsa et al., 2003; Rocca et al., 2008) but in contrast with previous
findings reporting positive associations between illness awareness and
adherence (Misdrahi et al., 2012; Mutsatsa et al., 2003; Rocca et al.,
2008). Interestingly none of the insight aspects predicted adherence in
terms of negative attitudes and medications side-effects. This finding
was also found by others (e.g., Misdrahi et al., 2012; Mutsatsa et al.,
2003) and might mean that for patients with insight, possible side-ef-
fects will not play significant role in adherence because they understand
and prioritize the positive consequences that treatment has.
The present study also found that internalized stigma predicted
lower adherence in accordance with previous findings (Hajda et al.,
2016; Livingston and Boyd, 2010; Yılmaz and Okanlı, 2015). This is
especially important considering the high rates of individuals with
mental illness that experience internalized stigma (Brohan et al., 2010).
Interestingly, adherence was also found to be negatively affected even if
patients do not necessarily internalize the stigma. However, even the
simple recognition of the existence of negative stereotypes in the so-
ciety towards mental illness or the agreement with these stereotypes
predicted lower adherence. More specifically, they were both predictors
of the adherence aspects related to negative attitudes regarding medi-
cation side-effects. This might be the reflection of the high stigma exists
towards psychiatric medications and their impact, perceiving them as
unnatural with harmful impact irrespective of its accuracy
(Angermeyer et al., 1993; Croghan et al., 2003; Horne, 1999;
Mojtabai, 2009). The importance in examining adherence was also
validated in the present study because non-adherence was found to be
significantly associated with lower quality of life, which also supported
by previous findings (Hayhurst et al., 2014; Puschner et al., 2009).
The present study might have some important clinical implications.
Perhaps the most significant one is the need in understanding that
patients’ subjective experience such as of stigma, loss, and grief while
coping with any mental illness is important, if not crucial in targeting
treatment adherence. As such, there is a need for an intervention plan
which will address such painful experiences. An example of an inter-
vention which has been found to increase insight (Yanos et al., 2012),
reduce internalized stigma, and improve patients quality of life
(Hansson et al., 2017; Roe et al., 2010) is Narrative Enhancement and
Cognitive Therapy (NECT) (Yanos et al., 2011). As the first step in
coping with grief is to accept the existence of loss (Worden, 1982),
acknowledging patients’ experience and defining it as a normal reaction
of grief, can facilitate patients’ acknowledgment and acceptance of their
experiences, illness, and perhaps also the need in treatment routine
(Young et al., 2004). Finding new meaning to life can also have healing
impact and reduce grief (Young et al., 2004). Another important im-
plication is that the study of grief might shed insight concerning an-
other critical and common problem in the psychiatry field – the lack of
insight (Pini et al., 2001). It is possible that what appears in many in-
stances as lack of insight might be a clear manifestation of grief
(Appelo et al., 1993; Mauritz and van Meijel, 2009; Young et al., 2004),
which has important implications for the treatment offered. Further-
more, the present study provided support for the application of the
MARS to the broader spectrum of mental diagnoses, and the need for
examining treatment adherence in diagnoses other than schizophrenia.
However, it might also raise the need to develop an illness-specific
adherence scale, especially because different diagnoses may carries
specific barriers to adherence (Velligan et al., 2010, 2009).
Importantly, the study findings are limited here in several aspects.
First, because the sample of the present study was diverse in terms of
diagnoses, patients were divided and grouped into main diagnostic
groups. Therefore, the detection of differences which might exist be-
tween diagnoses in the same groups was not possible. Moreover, this
specific grouping might compromise the generalization of the results to
these diagnostic groups. This should be addressed in future studies by
examining adherence in more specific and larger diagnostic groups.
Another factor which might limit the generalization of the study results
is the convenience sample utilized and the inclusion of a relatively
stable and functioning sample. Second, as the present study was cross-
sectional, cause and effect patterns between variables cannot be ver-
ified, and the impact of third variables cannot be excluded. Finally,
adherence was assessed by patients’ self-report, which is known for
inaccuracies (Sajatovic et al., 2010). However, other measurements are
also known for their inaccuracies (Velligan et al., 2006), and focusing
on patients’ perspectives was preferable for the present study in ex-
amining patients’ subjective experience.
In spite of the limitations presented, the present study offers valu-
able insights to the study of medication adherence. These mainly in-
clude the importance of examining non-adherence in a broader range of
diagnoses and of focusing on patients’ grief and loss while tackling
adherence problems. This might be especially important in order to
help patients come to terms with their illness, the need for treatment,
and in finding new meaning and goals for life, which will facilitate
adherence, healing, and a better quality of life.
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